rs7597593

Meta-analysis of ZNF804A SNPs in 13,452 schizophrenia cases and 17,826 controls from Asian populations found that rs1344706 was nominally associated with schizophrenia (P=4.26×10⁻², OR=1.048) and rs1366842 showed significant association (P=9.96×10⁻³, OR=1.095). These associations were strengthened when bipolar disorder samples were included (rs1344706: P=1.85×10⁻², OR=1.057), suggesting ZNF804A variants confer small but detectable risk for schizophrenia and related psychotic disorders in Asian populations.

This association study examined two ZNF804A polymorphisms (rs7597593 and rs1344706) in 706 non-clinical subjects for associations with positive schizotypy and psychotic-like experiences. rs7597593 showed significant associations with both traits (F=5.06, p=0.007 for schizotypy; F=4.07, p=0.02 for psychotic experiences), with effects driven by females—those carrying the C allele had higher scores than TT homozygotes. No significant associations were detected for rs1344706.

This comprehensive review examines the genomics of schizophrenia and pharmacogenomics of antipsychotic drugs, synthesizing evidence on over 200 genes associated with psychotic disorders. The authors discuss five categories of genes relevant to antipsychotic response: disease-associated genes, mechanism-of-action genes, drug metabolism genes (particularly CYP2D6, CYP2C19, CYP2C9, CYP3A4), drug transporter genes, and pleiotropic genes. The review details pharmacogenomic profiles of 20+ antipsychotic drugs and demonstrates significant ethnic and interindividual variation in drug metabolism phenotypes, with examples including CYP2D6 extensive metabolizers (55.71% of population), intermediate metabolizers (34.7%), poor metabolizers (2.28%), and ultra-rapid metabolizers (7.31%).

This comprehensive review synthesizes genomic and pharmacogenomic research in schizophrenia, discussing over 200 candidate genes associated with psychotic disorders, genetic mechanisms including copy number variants and microRNA alterations, and pharmacogenomic factors affecting antipsychotic efficacy and safety. Key genes covered include dopamine receptors (DRD1-5), dysbindin (DTNBP1), DISC1, neurotrophic factors, and metabolic enzymes such as CYP2D6, CYP3A4, and COMT, with emphasis on genotype-phenotype correlations in antipsychotic response and side effects.